注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。
药融圈监测显示：近期，2025年12月17日经百济神州公司董事会审议通过，汪来进一步被聘任为总裁，全球研发负责人。，全面负责研发、业务拓展及业务联盟关系管理等核心职能。
关于汪来的英文公告说明，薪资待遇激励惊人。
On December 17, 2025, BeOne Medicines Ltd. (the “Company”) appointed Dr. Lai Wang to serve as President, Global Head of Research and Development of the Company. In this role, Dr. Wang will oversee the research and development functions as well as other functions, including business development and alliance management.
Dr. Wang, age 48, has served as the Company’s Global Head of Research and Development since April 2021. Prior to that, he held various research and development leadership roles with increasing responsibilities since he joined the Company in 2011. Prior to joining the Company, Dr. Wang was Director of Research at Joyant Pharmaceuticals. Dr. Wang received a B.S. from Fudan University in 1996 and a Ph.D. from the University of Texas Health Science Center at San Antonio in 2001.
In his new role, effective January 1, 2026, Dr. Wang will receive an annual salary of $750,000, subject to increase at the discretion of the Board of Directors or its designated committee, and is eligible for an annual target bonus equal to 75% of his base salary, subject to individual and corporate performance, in accordance with the Company’s annual bonus plan. In recognition of Dr. Wang’s promotion, the Company will grant him a one-time equity incentive award of $10,000,000 in the form of restricted share units, which will vest in four equal annual installments, subject to accelerated vesting upon certain specified termination events pursuant to the terms of his employment agreement. The terms and conditions of Dr. Wang’s compensation are consistent with his employment agreement as previously disclosed and the Company’s compensation plans and programs as set forth in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 7, 2025.
There are no other arrangements or understandings between Dr. Wang and any other persons pursuant to which Dr. Wang was appointed as President, Global Head of Research and Development of the Company. There are no family relationships between Dr. Wang and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
参考资料：
药融圈数据；
摩熵医药pharma.bcpmdata.com（原药融云数据）；
https://www.businesswire.com；百济神州；
https://www.sec.gov/Archives/edgar/data/1651308/000165130825000151/0001651308-25-000151-index.htm；
等等。
